• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

阿替利珠单抗联合贝伐珠单抗：肝细胞癌的新突破。

Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma.

机构信息

Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain.

Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

出版信息

Clin Cancer Res. 2021 Apr 1;27(7):1827-1829. doi: 10.1158/1078-0432.CCR-20-4706. Epub 2021 Jan 20.

DOI:10.1158/1078-0432.CCR-20-4706
PMID:33472912
Abstract

The combination of atezolizumab and bevacizumab increases overall survival compared with sorafenib in advanced hepatocellular carcinoma (HCC). Its approval by the FDA has launched a new era of combination therapies in advanced and earlier settings that are likely to reshape the management of HCC across all disease stages..

摘要

阿替利珠单抗联合贝伐珠单抗相较于索拉非尼可提高晚期肝细胞癌（HCC）患者的总生存期。该药获 FDA 批准，开启了晚期及早期治疗中联合治疗的新时代，有望重塑各疾病阶段 HCC 的治疗管理模式。

相似文献

1
Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗：肝细胞癌的新突破。
Clin Cancer Res. 2021 Apr 1;27(7):1827-1829. doi: 10.1158/1078-0432.CCR-20-4706. Epub 2021 Jan 20.
2
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.单细胞RNA测序衍生的特征定义了晚期肝细胞癌对阿替利珠单抗+贝伐单抗的反应模式。
J Hepatol. 2025 Jun;82(6):1036-1049. doi: 10.1016/j.jhep.2024.12.016. Epub 2024 Dec 19.
3
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial.托法替布联合贝伐珠单抗对比索拉非尼作为晚期肝细胞癌一线治疗的疗效（HEPATORCH）：一项随机、开放标签的3期试验
Lancet Gastroenterol Hepatol. 2025 Jul;10(7):658-670. doi: 10.1016/S2468-1253(25)00059-7. Epub 2025 May 20.
4
Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma-a multicentric study.阿替利珠单抗/贝伐珠单抗治疗不可切除肝细胞癌的安全性和有效性——一项多中心研究
BMC Cancer. 2025 Jul 1;25(1):1026. doi: 10.1186/s12885-025-14400-9.
5
Evaluating the cost-effectiveness of atezolizumab-bevacizumab in advanced hepatocellular carcinoma: Insights from Taiwan.评估阿替利珠单抗联合贝伐珠单抗治疗晚期肝细胞癌的成本效益：来自台湾的见解。
J Food Drug Anal. 2025 Jun 13;33(2):163-171. doi: 10.38212/2224-6614.3542.
6
Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study.在高肿瘤负荷的不可切除肝细胞癌中，乐伐替尼和替雷利珠单抗对比阿替利珠单抗和贝伐单抗联合经动脉化疗栓塞性肝动脉灌注化疗：一项多中心回顾性队列研究
Cancer Immunol Immunother. 2025 Feb 1;74(3):88. doi: 10.1007/s00262-025-03942-3.
7
Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials.免疫肿瘤学时代中晚期肝细胞癌的经动脉和靶向治疗的排名：随机索拉非尼对照试验的网络荟萃分析。
Hepatol Commun. 2022 Oct;6(10):2886-2900. doi: 10.1002/hep4.2025. Epub 2022 Jul 4.
8
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.不可切除的早中期肝细胞癌根治性转化治疗后阿替利珠单抗联合贝伐单抗停药标准的提议：一项多中心概念验证研究
J Gastroenterol. 2025 Jun;60(6):738-753. doi: 10.1007/s00535-025-02233-z. Epub 2025 Mar 7.
9
Classification and Regression Trees to Predict for Survival for Patients With Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab.基于阿替利珠单抗和贝伐珠单抗治疗的肝细胞癌患者的生存预测的分类和回归树。
JCO Clin Cancer Inform. 2024 Aug;8:e2300220. doi: 10.1200/CCI.23.00220.
10
Efficacy and Safety of Lenvatinib versus Atezolizumab Plus Bevacizumab in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.仑伐替尼对比阿替利珠单抗联合贝伐单抗治疗不可切除肝细胞癌的疗效与安全性：一项系统评价和荟萃分析
Asian Pac J Cancer Prev. 2025 May 1;26(5):1529-1542. doi: 10.31557/APJCP.2025.26.5.1529.

引用本文的文献

1
Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review.代谢功能障碍相关脂肪性肝炎相关肝细胞癌的发病机制与管理：一篇叙述性综述
Ewha Med J. 2024 Oct;47(4):e65. doi: 10.12771/emj.2024.e65. Epub 2024 Oct 31.
2
Targeting Metabolism: Innovative Therapies for MASLD Unveiled.靶向代谢：非酒精性脂肪性肝炎的创新疗法揭秘。
Int J Mol Sci. 2025 Apr 25;26(9):4077. doi: 10.3390/ijms26094077.
3
Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies with curative potential.
肝细胞癌治疗中靶向免疫检查点：迈向具有治愈潜力的联合策略
Exp Hematol Oncol. 2025 May 2;14(1):65. doi: 10.1186/s40164-025-00636-5.
4
Structural insights into antibody-based immunotherapy for hepatocellular carcinoma.基于抗体的肝细胞癌免疫治疗的结构见解
Genomics Inform. 2025 Jan 20;23(1):1. doi: 10.1186/s44342-024-00033-0.
5
IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study.IMbrave150：阿替利珠单抗联合贝伐单抗与索拉非尼治疗巴塞罗那临床肝癌分期B期不可切除肝细胞癌患者的疗效和安全性：一项III期研究的探索性分析
Liver Cancer. 2022 Nov 28;12(3):238-250. doi: 10.1159/000528272. eCollection 2023 Aug.
6
Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy.血管生成和免疫检查点双重阻断：肝细胞癌治疗的机遇与挑战。
World J Gastroenterol. 2022 Nov 14;28(42):6034-6044. doi: 10.3748/wjg.v28.i42.6034.
7
Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers.胃肠道和肝胆癌中当前及新兴的抗血管生成疗法
Front Oncol. 2022 Oct 10;12:1021772. doi: 10.3389/fonc.2022.1021772. eCollection 2022.
8
Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial.经导管动脉化疗栓塞术前后放疗治疗伴有门静脉癌栓的肝细胞癌：一项随机对照试验。
Hepatol Int. 2022 Dec;16(6):1368-1378. doi: 10.1007/s12072-022-10423-7. Epub 2022 Oct 21.
9
Clinically approved combination immunotherapy: Current status, limitations, and future perspective.临床批准的联合免疫疗法：现状、局限性及未来展望。
Curr Res Immunol. 2022 Jun 3;3:118-127. doi: 10.1016/j.crimmu.2022.05.003. eCollection 2022.
10
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.炎症和非炎症 HCC 分类：一种修正的免疫基因组分类。
Gut. 2023 Jan;72(1):129-140. doi: 10.1136/gutjnl-2021-325918. Epub 2022 Feb 23.